Edition:
United States

VIVUS Inc (VVUS.O)

VVUS.O on Nasdaq

1.12USD
25 May 2017
Change (% chg)

$0.02 (+1.82%)
Prev Close
$1.10
Open
$1.13
Day's High
$1.13
Day's Low
$1.10
Volume
802,920
Avg. Vol
618,830
52-wk High
$1.47
52-wk Low
$0.93

VVUS.O

Chart for VVUS.O

About

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA... (more)

Overall

Beta: 0.95
Market Cap(Mil.): $116.25
Shares Outstanding(Mil.): 105.68
Dividend: --
Yield (%): --

Financials

  VVUS.O Industry Sector
P/E (TTM): 3.43 14.35 17.42
EPS (TTM): 0.32 -- --
ROI: 14.94 -7.29 -5.45
ROE: -- -6.80 -4.73

BRIEF-Vivus reports Q1 loss per share $0.01

* Total revenue, net for first quarters of 2017 and 2016, was $27.0 million and $15.3 million, respectively

May 03 2017

BRIEF-Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi

* Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi

Mar 27 2017

BRIEF-Vivus entered into settlement agreement with Hetero on Jan. 3

* On Jan 3, co entered into a settlement agreement with hetero - sec filing

Jan 09 2017

BRIEF-Vivus and Selten Pharma announce agreement for development and commercialization rights to treatments for PAH

* Vivus and Selten Pharma announce agreement for the development and commercialization rights to treatments for Pulmonary Arterial Hypertension (PAH)

Jan 09 2017

More From Around the Web

Competitors

Earnings vs. Estimates